Pakuvhara MYND yakapa 450,000 common shares (“Shares”) kuCava nemutengo unofungidzirwa we$0.85 per share uye yakaita mubhadharo wemari we$120,000 sekufunga nezveZvakatorwa Asset. Pamusoro pezvo, MYND ichabhadhara kuCava humambo hwepagore hwakaenzana nehukuru hwe: (i) $240,000; kana (ii) 4% yekutengeswa kwese kwechero chigadzirwa kana sevhisi iyo yakananga kana zvisina kunanga inosanganisira iyo Yakawanikwa Asset kune chero bato rechitatu.
Iyo Migove ichave iri pasi pemutemo wekubata nguva inopera pazuva iro mwedzi mina (4) uye zuva rimwe kubva pazuva rekuvhara.
Dementia inoparadza neurodegenerative mamiriro ayo anotungamira mukuora kwakanyanya kwekuziva muvanhu vakuru uye kuwedzera nezera. Sangano reWorld Health Organisation rinoti vanhu vari pakati pemamiriyoni makumi mana nemana kusvika makumi mashanu pasi rose vanorwara nedementia. Mari inofungidzirwa yekuchengeta vanhu vane dementia, kusanganisira Chirwere cheAlzheimer, muU.SA chete, yakanga iri mabhiriyoni mazana matatu neshanu emadhora muna 44 (kunobva: Alzheimer's Association) uye inotarisirwa kusvika madhora miriyoni gumi nemazana maviri panosvika 50. Huwandu hwevanhu vekuAmerica vari kurarama nechirwere cheAlzheimer. inofungidzirwa kuti ichapeta katatu ne305 kunze kwekunge kuvandudzwa kwehutano hwekurapa kwaitwa. MYND inotarisira kuve pamberi peidzi budiriro.
“Kuora mwoyo, kubatanidza hosha yeAlzheimer, kunobata dzinenge mhuri dzose neimwe nzira, kazhinji nemigumisiro inoshamisa zvikuru uye inorwadza mupfungwa,” anotsanangura kudaro Dr. Lyle Oberg, MD, CEO weMYND. "Apo isu tichiramba tichikwevera kufarira kwevanoisa mari, tinokwanisa kutora matanho anobatika ekufamba kupfuura preclinical uye kuita basa rekiriniki nechikwata chedu chekutsvagisa."
Kutorwa kwacho chiratidzo chakakosha cheMYND uye kunovakira pachiitiko chakakosha cheMYND muchikamu chepsilocybin-assisted psychotherapy sector, kusanganisira nzira dzekuora mwoyo kusingaite, pasi pehutungamiriri hwaDr. Lyle Oberg, MD, MYND CEO.
VaTheo Warkentin, Cava CEO, vakati, "MYND inotungamira indasitiri mune psychedelic psychotherapy, therapeutics uye diagnostics. Iyo kambani yakamisikidzwa yakasarudzika yekutevera kushanda kwepsilocybin nemamwe psychedelics ekurapa dementias. "
ZVOKUBVA MUNYAYA INO:
- The acquisition is a key landmark for MYND and it builds upon MYND’s significant experience in the psilocybin-assisted psychotherapy sector, including methods for treatment-resistant depression, under the leadership of Dr.
- Iyo Migove ichave iri pasi pemutemo wekubata nguva inopera pazuva iro mwedzi mina (4) uye zuva rimwe kubva pazuva rekuvhara.
- The estimated cost of caring for people with dementia, including Alzheimer’s Disease, in the USA alone, was a staggering $305 billion in 2020 (source.
